SPS01 - Harmonize your UK and EU CTA submissions: Practical strategies from EU-CTR experience
Information
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new opportunities for clinical trial applications (CTAs), while the broader European regulatory landscape continues to evolve with initiatives like FAST-EU, targeting multinational clinical trials. How can sponsors effectively navigate these changes?
This session provides practical guidance for leveraging MHRA's new CTA framework while applying critical insights from EU-CTR implementation, considering a global strategy. We explore approaches for harmonising submissions across UK and EU regulatory systems, identifying potential challenges, and implementing proactive solutions. Through expert analysis, sponsors will gain a clear roadmap for maximizing efficiency and accelerating patient access to innovative treatments.
AI-generated summary
This session provides practical strategies for harmonizing UK and EU Clinical Trial Application (CTA) submissions to accelerate approval timelines, maximize efficiency, and enhance patient access to innovative treatments.
Takeaways
- Benefits of Harmonized Submissions: A harmonized strategy for UK and EU CTA submissions minimizes redundant work, accelerates approval timelines, and is crucial for faster patient recruitment and access to new drugs in critical markets.
- EU Regulatory Landscape: The EU Clinical Trial Regulation (EU-CTR) mandates synchronized submissions via CTIS, with the voluntary FAST-EU pilot aiming for accelerated 70-day approvals for multinational trials, emphasizing fast, consolidated RFI responses.
- UK Regulatory Changes: The UK's new regulatory framework, effective April 2026, offers benefits like defined validation periods, extended RFI response times (60 days), and expedited pathways for notifiable trials, allowing faster progression if responses are prompt.
- Strategic Submission Approach: Submitting to MHRA first can provide valuable feedback to strengthen EU-CTR applications, leveraging the UK's flexibility for novel designs and potentially faster initial decisions, creating a cross-learning advantage between the two systems.
- Maximizing Combined Submission Benefits: Achieving success requires combining submissions within a few weeks, meeting higher documentation standards, building adaptive protocols, ensuring transparent communication with assessors, and early engagement with investigators to streamline processes.
Buzzwords
- Harmonized Submissions
- Clinical Trial Applications (CTAs)
- Regulatory Strategy
- Patient Access
- MHRA / EU-CTR
Memorable Quotes
- Esther Gil Lopez: This harmonized strategy will minimize redundant work to prepare separate dossiers for both regions. And with these submissions going in parallel, we will accelerate approval timelines.
- Esther Gil Lopez: MHRA approval can open also doors in Europe. So having this strategy initiating UK ahead of the EU can optimize our timelines.
- Esther Gil Lopez: If we submit to the UK, we will receive feedback from the MHRA that will be used in our dossier for EU clinical trial regulation application. And then once we receive feedback from Europe, this feedback can be used to strengthen the amendments in the UK.
- Esther Gil Lopez: The benefits are accelerated patient access to these new drugs. We can save between four and eight weeks to first patient enroll. And also maximize efficiency, reducing even 40% of resources assigned to the project.
- Esther Gil Lopez: Harmonize submissions in the UK and Europe is totally beneficial and achievable.
